Immediate Impact
1 by Nobel laureates 66 standout
Citing Papers
Defining clinically useful biomarkers of immune checkpoint inhibitors in solid tumours
2024 Standout
Tertiary lymphoid structures in anticancer immunity
2024 Standout
Works of Ye Zhou being referenced
CheckMate 012: Safety and efficacy of first-line (1L) nivolumab (nivo; N) and ipilimumab (ipi; I) in advanced (adv) NSCLC.
2016
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Ye Zhou | 117 | 71 | 52 | 73 | 39 | 408 | |
| Jun Liu | 111 | 85 | 31 | 46 | 28 | 402 | |
| Harun Ülger | 155 | 34 | 36 | 29 | 44 | 427 | |
| Yan Zhao | 131 | 51 | 41 | 34 | 55 | 454 | |
| Honglei Tu | 183 | 52 | 30 | 84 | 24 | 425 | |
| Ying Tian | 113 | 24 | 72 | 41 | 37 | 444 | |
| Guojun Wu | 160 | 43 | 18 | 43 | 33 | 350 | |
| Shuang Hu | 126 | 43 | 18 | 32 | 35 | 396 | |
| Mehdi Sahmani | 172 | 28 | 13 | 39 | 32 | 443 | |
| Farshid Fathi | 74 | 91 | 19 | 51 | 21 | 356 | |
| Mehri Azadbakht | 113 | 70 | 25 | 30 | 50 | 396 |
All Works
Loading papers...